Anthony Ting

Anthony Ting serves as the Chief Scientific Officer at Kiji Therapeutics, leading efforts in developing innovative engineered cell therapies for severe diseases since November 2023. With a robust background in cell and gene therapy, Anthony holds a principal position at BRL C&GT Consulting, providing expertise in IND-enabling study design and clinical development strategies. Anthony also serves as Chief Commercialization Officer and Board Member for ISCT and is an Advisory Board Member for TrueTrials, assisting patients in finding FDA-authorized clinical trials. Previous roles include Program Leader in Oncology Cell Therapy Innovation at Takeda and Chief Scientific Officer at BONE THERAPEUTICS S.A. Anthony's long tenure at Athersys as Vice President of Regenerative Medicine encompassed leading cardiovascular and pulmonary research initiatives. Academic credentials include post-doctoral studies at Stanford University and a Ph.D. from The Johns Hopkins University.